Consideration of ethics in primaquine therapy against malaria transmission.
about
A long neglected world malaria map: Plasmodium vivax endemicity in 2010Primaquine for reducing Plasmodium falciparum transmissionEthical aspects of malaria control and researchRationale for short course primaquine in Africa to interrupt malaria transmissionA genome wide association study of Plasmodium falciparum susceptibility to 22 antimalarial drugs in KenyaTransmission-blocking strategies: the roadmap from laboratory bench to the communityG6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based mapEthics, economics, and the use of primaquine to reduce falciparum malaria transmission in asymptomatic populationsG6PD deficiency in Latin America: systematic review on prevalence and variantsThe challenges of introducing routine G6PD testing into radical cure: a workshop report.First evaluation of glucose-6-phosphate dehydrogenase (G6PD) deficiency in vivax malaria endemic regions in the Republic of Korea.Glucose-6-phosphate dehydrogenase deficiency in people living in malaria endemic districts of NepalDonor support for quality assurance and pharmacovigilance of anti-malarials in malaria-endemic countries.Performance of the CareStart™ G6PD deficiency screening test, a point-of-care diagnostic for primaquine therapy screeningEpidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and eliminationElimination therapy for the endemic malarias.Plasmodium vivax malaria endemicity in Indonesia in 2010.A class of tricyclic compounds blocking malaria parasite oocyst development and transmission.A quantitative high throughput assay for identifying gametocytocidal compoundsA malaria gametocytocidal assay using oxidoreduction indicator, alamarBlueImproving the radical cure of vivax malaria (IMPROV): a study protocol for a multicentre randomised, placebo-controlled comparison of short and long course primaquine regimens.Genetic diversity of transmission-blocking vaccine candidate Pvs48/45 in Plasmodium vivax populations in ChinaReinventing primaquine for endemic malaria.Ivermectin to reduce malaria transmission: a research agenda for a promising new tool for eliminationTools for mass screening of G6PD deficiency: validation of the WST8/1-methoxy-PMS enzymatic assay in Uganda.Nonrandomized controlled trial of artesunate plus sulfadoxine-pyrimethamine with or without primaquine for preventing posttreatment circulation of Plasmodium falciparum gametocytes.Spatial distribution of G6PD deficiency variants across malaria-endemic regions.Retinopathy of vivax malaria in adults and its relation with severity parametersChemical signatures and new drug targets for gametocytocidal drug development.The prevalence of glucose-6-phosphate dehydrogenase deficiency in Gambian school childrenNovel approaches in antimalarial drug discovery.An in vivo drug screening model using glucose-6-phosphate dehydrogenase deficient mice to predict the hemolytic toxicity of 8-aminoquinolines.Antiplasmodial activity study of angiotensin II via Ala scan analogs.Haemolysis risk in methylene blue treatment of G6PD-sufficient and G6PD-deficient West-African children with uncomplicated falciparum malaria: a synopsis of four RCTs.Blocking Plasmodium falciparum Malaria Transmission with Drugs: The Gametocytocidal and Sporontocidal Properties of Current and Prospective Antimalarials.Prevalence of glucose-6-phosphate dehydrogenase (G6PD) deficiency among malaria patients in Upper Myanmar.Diagnosis and Treatment of Plasmodium vivax Malaria.
P2860
Q21144495-CEEA61E5-4DCB-4EAB-A893-51314591E080Q24200471-A3D28261-D77B-4859-895D-44FA18C42233Q26773470-65BB4121-7F48-445F-92F8-A16BD51FAAC4Q27006552-8B877A8B-BADF-4EF9-8CA7-DF36E857C68EQ28031418-5A4E43D2-6225-488D-901D-342F2F6F79A0Q28078982-ED496EDB-5219-4815-B53A-7A489E792E03Q28485156-D0E9CF1F-04D8-40FB-B939-CC11EE1E6A04Q28542069-3B66A289-5C62-48AC-9977-A7F6FEC9ACEAQ29353696-E963C544-2F61-4AA5-8732-B67BB219CFBEQ30666192-D4468137-5AFC-4564-B35A-706865816E61Q33650302-158B0BE2-E63E-40A5-BE0C-62A89BE46D21Q33721887-63CD6AE7-5AE2-465D-A9D5-889768863361Q33892227-B717E1BC-728E-471E-A0E6-01D079B362BDQ34099217-A63B3452-E00B-4FD0-AECE-18F1727CC371Q34177472-11560506-E5C0-423A-B880-E045D708EC71Q34194828-5BF6B82C-55A9-4E80-BD20-A1898780A1D0Q34277987-C71A200C-AD3F-44AD-AE1D-858CB56C156EQ34467923-1045B40E-A581-4052-8E3E-B7C2D508A2C8Q34605248-708D232F-20DC-49F5-9CF0-0788FB394564Q34786064-2F6B45EB-3641-476D-90A2-C3AA03E5ABA2Q35862811-55002BFA-2D84-4375-B08F-535A7DE4F721Q36336302-59341A36-323E-42A2-B73E-4CF5260B3FFFQ36444170-D19F026B-F144-4D2B-BB6C-CD69D3627289Q36858823-8A3E1240-F258-4D43-A974-FA00185E0245Q36952371-E802CF3C-4C10-4FE9-BD69-61116D13181CQ36969682-65D42E24-5929-43CF-8A60-865A46C9D9CEQ37329332-538894A8-7BD5-4087-8C6C-F7815208232EQ37353315-519D182C-38CC-4E43-A7FC-12D7709F2609Q37489274-795E07A9-C868-44FB-8719-E63D3A5FDA95Q37723447-8C27EECF-15E2-4556-A762-CA17AFCF57EEQ38148787-0A0C7FA6-51FC-4B84-84DD-91E2608F95AFQ41926337-5F7E0AAC-A864-4D3A-B49B-FA9B40412E90Q43034707-BEC01444-E493-4407-97FA-4E226A803334Q43929062-59A7A337-6987-4C69-9124-95D4BB696203Q47169530-E0C84FE9-706D-4864-8BFF-5B25F36DA8F0Q51762424-305189D0-2D8B-483A-9219-5604C74F51C7Q53767337-F7950B39-E52F-4F39-9569-0DB477B184DE
P2860
Consideration of ethics in primaquine therapy against malaria transmission.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Consideration of ethics in primaquine therapy against malaria transmission.
@ast
Consideration of ethics in primaquine therapy against malaria transmission.
@en
type
label
Consideration of ethics in primaquine therapy against malaria transmission.
@ast
Consideration of ethics in primaquine therapy against malaria transmission.
@en
prefLabel
Consideration of ethics in primaquine therapy against malaria transmission.
@ast
Consideration of ethics in primaquine therapy against malaria transmission.
@en
P921
P356
P1476
Consideration of ethics in primaquine therapy against malaria transmission.
@en
P2093
Claudia Surjadjaja
P356
10.1016/J.PT.2010.08.005
P577
2010-09-16T00:00:00Z